| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Yong Liu | |
| Wei Ma | |||
| Zhiwei Zhang | |||
| Yuxuan Li | |||
| Yiyang Xiao | |||
| Gaosheng Xu | |||
| Dong Mei Ye | |||
| Weiru Luo | |||
| P2860 | cites work | What are biomarkers? | Q24613362 |
| Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy | Q24635408 | ||
| Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits | Q27333657 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence | Q27851725 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| HER2 testing in gastric cancer: a practical approach | Q28256814 | ||
| The BCL-2 protein family: opposing activities that mediate cell death | Q29547380 | ||
| Landscape of transcription in human cells | Q29547467 | ||
| Modular regulatory principles of large non-coding RNAs | Q29617829 | ||
| Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs | Q29618428 | ||
| The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification | Q29618627 | ||
| Circular RNAs are a large class of animal RNAs with regulatory potency | Q29620042 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 | ||
| Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers | Q30652890 | ||
| Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers | Q33422778 | ||
| International Programme on Chemical Safety (IPCS) environmental health criteria on boron human health risk assessment | Q33537383 | ||
| Entire-volume serial histological examination for detection of micrometastases in lymph nodes of colorectal cancers | Q33980405 | ||
| Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis | Q34089030 | ||
| Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. | Q34160896 | ||
| Circular RNAs: splicing's enigma variations | Q34331123 | ||
| Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer | Q34544166 | ||
| Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. | Q34554455 | ||
| Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer | Q35011130 | ||
| Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. | Q35108424 | ||
| Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer | Q35113261 | ||
| Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy | Q35154288 | ||
| Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer | Q35764908 | ||
| MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1 | Q35853031 | ||
| Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity | Q35870655 | ||
| Intrinsic tumour suppression | Q35953133 | ||
| Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells | Q36157132 | ||
| A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer | Q36306554 | ||
| Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival | Q36308479 | ||
| Global DNA hypomethylation is an early event in Helicobacter pylori-related gastric carcinogenesis | Q84205139 | ||
| [The latest 2010 WHO classification of tumors of digestive system] | Q84560118 | ||
| Prognostic impact of CD133 expression in gastric carcinoma | Q84586885 | ||
| Expression of apoptosis-related proteins and its clinical implication in surgically resected gastric carcinoma | Q84987698 | ||
| Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma | Q85785866 | ||
| Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer | Q87494688 | ||
| Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance | Q87827796 | ||
| Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67 | Q88779898 | ||
| Erratum to: Past and current trends in endoscopic diagnosis for early stage gastric cancer in Japan | Q89471281 | ||
| Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving surgery | Q90169792 | ||
| FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 | Q91011455 | ||
| Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level | Q92733382 | ||
| Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer | Q95385234 | ||
| Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance | Q39024400 | ||
| Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls | Q39037474 | ||
| Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer | Q39299196 | ||
| Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells | Q39317613 | ||
| Long noncoding RNAs: lincs between human health and disease | Q39376908 | ||
| Alteration of DNA Methylation in Gastric Cancer with Chemotherapy | Q39377814 | ||
| MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer | Q39458980 | ||
| Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. | Q39736030 | ||
| EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number | Q40105232 | ||
| PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies | Q40185070 | ||
| Gastric Cancer as Preventable Disease | Q40203177 | ||
| Gastric cancer screening using the serum pepsinogen test method | Q40250560 | ||
| A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study | Q40282956 | ||
| Spreading of methylation within RUNX3 CpG island in gastric cancer | Q40338066 | ||
| Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLO | Q40487371 | ||
| Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability | Q40503160 | ||
| Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique | Q40904978 | ||
| Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. | Q41038524 | ||
| Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. | Q41228724 | ||
| MiR-219-5p Inhibits the Growth and Metastasis of Malignant Melanoma by Targeting BCL-2. | Q41528572 | ||
| Current status of lymph node micrometastasis in gastric cancer | Q41613126 | ||
| Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role | Q41674960 | ||
| Serum pepsinogens as a screening test of extensive chronic gastritis. | Q42523163 | ||
| Helicobacter pylori and CagA status, serum gastrin, interleukin-8 and gastric acid secretion in gastric cancer | Q42525913 | ||
| Disparities in gastric cancer chemotherapy between the East and West | Q36472210 | ||
| Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. | Q36616006 | ||
| Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. | Q36661984 | ||
| Missed diagnosis of early gastric cancer or high-grade intraepithelial neoplasia | Q36759235 | ||
| Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial | Q36892840 | ||
| MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. | Q37028111 | ||
| HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 | ||
| Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers | Q37362803 | ||
| Thrombosis associated with angiogenesis inhibitors. | Q37414595 | ||
| Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer | Q37468314 | ||
| Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial | Q37491940 | ||
| Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer | Q37495918 | ||
| The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia | Q37517482 | ||
| Ki67 in breast cancer: prognostic and predictive potential | Q37691691 | ||
| MicroRNA dysregulation in gastric cancer: a new player enters the game | Q37783909 | ||
| mTOR as a therapeutic target in patients with gastric cancer | Q37928535 | ||
| Molecular pathology of gastric cancer: research and practice | Q37946590 | ||
| Novel targeted agents for gastric cancer | Q38019657 | ||
| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial | Q38099726 | ||
| Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway | Q38126246 | ||
| Long noncoding RNAs: emerging stars in gene regulation, epigenetics and human disease. | Q38200054 | ||
| Review article: the epidemiology and prevention of gastric cancer | Q38218870 | ||
| Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. | Q38352301 | ||
| Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil | Q38490073 | ||
| Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. | Q38659483 | ||
| Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer | Q38708974 | ||
| Circular RNA 0000096 affects cell growth and migration in gastric cancer | Q38721690 | ||
| A global burden of gastric cancer: the major impact of China. | Q38738402 | ||
| The emerging landscape of circular RNA in life processes. | Q38822247 | ||
| Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | Q38829062 | ||
| Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). | Q38833332 | ||
| Aberrant expression of UCA1 in gastric cancer and its clinical significance | Q38883468 | ||
| Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? | Q38921936 | ||
| The emerging role and clinical implication of human exonic circular RNA. | Q38944775 | ||
| Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial | Q42693879 | ||
| Clinical significance of RacGAP1 expression at the invasive front of gastric cancer | Q43781232 | ||
| Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients | Q44559861 | ||
| Global burden of gastric cancer attributable to Helicobacter pylori | Q44946941 | ||
| Histologic and serum risk markers for noncardia early gastric cancer | Q45249201 | ||
| Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. | Q45953253 | ||
| A study on the prognostic value of cyclins D1 and E expression levels in resectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes. | Q46791001 | ||
| MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas | Q46799794 | ||
| Expression of pRb, Ki67 and HER 2/neu in gastric carcinomas: Relation to different histopathological grades and stages | Q46894370 | ||
| Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients | Q46896443 | ||
| Does histology really influence gastric cancer prognosis? | Q47126414 | ||
| Tumor Mutational Burden and Response Rate to PD-1 Inhibition. | Q47270933 | ||
| Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines | Q47573694 | ||
| The relevance of gastric cancer biomarkers in prognosis and pre- and post- chemotherapy in clinical practice | Q47635690 | ||
| A soluble protein characteristic of the nervous system | Q47721048 | ||
| Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q47745009 | ||
| Re-evaluation of mucin phenotypes of gastric minute well-differentiated-type adenocarcinomas using a series of HGM, MUC5AC, MUC6, M-GGMC, MUC2 and CD10 stains | Q47757355 | ||
| Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma | Q47864236 | ||
| The cadherin superfamily at the synapse: more members, more missions | Q47872691 | ||
| Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. | Q50146512 | ||
| Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. | Q50774778 | ||
| Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. | Q50947118 | ||
| Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. | Q52586565 | ||
| c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. | Q52632856 | ||
| Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. | Q52640577 | ||
| [Updates and interpretation on NCCN clinical practice guidelines for gastric cancer 2017 version 5]. | Q52680204 | ||
| The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer. | Q52923628 | ||
| Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. | Q52941241 | ||
| Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. | Q53249720 | ||
| Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. | Q53265398 | ||
| Using circular RNA as a novel type of biomarker in the screening of gastric cancer. | Q53605746 | ||
| C-MET inhibitors for advanced non-small cell lung cancer. | Q53698087 | ||
| Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. | Q53837214 | ||
| Using circular RNA hsa_circ_0000190 as a new biomarker in the diagnosis of gastric cancer. | Q54130195 | ||
| Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. | Q55322223 | ||
| Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer | Q56892328 | ||
| Gastric cancer | Q57758203 | ||
| Circular RNA YAP1 inhibits the proliferation and invasion of gastric cancer cells by regulating the miR-367-5p/p27 axis | Q58599825 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity | Q70141373 | ||
| Carcinoembryonic antigen in gastric juice as an aid in diagnosis of early gastric cancer | Q71431907 | ||
| Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994 | Q72152032 | ||
| The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma | Q72992712 | ||
| NIH-FDA Conference: Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications. Abstracts | Q73038254 | ||
| Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer | Q73369326 | ||
| Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas | Q73370164 | ||
| Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer | Q73387820 | ||
| Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer | Q80525682 | ||
| DNA methylation and cancer | Q81002014 | ||
| Lymphatic and blood vessel density in the follicular patterned lesions of thyroid | Q81791420 | ||
| P433 | issue | 1 | |
| P921 | main subject | biomarker | Q864574 |
| research progress | Q122351028 | ||
| P304 | page(s) | 17-29 | |
| P577 | publication date | 2019-11-11 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | Significant function and research progress of biomarkers in gastric cancer | |
| P478 | volume | 19 |
Search more.